A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 1, 2015, Pages 87-95

  Sharma, Sunil ^a   Witteveen, Petronella O ^b   Lolkema, Martijn P ^b   Hess, Dagmar ^c   Gelderblom, Hans ^d   Hussain, Syed A ^e   Porro, Maria G ^f   Waldron, Edward ^f   Valera, Sue Zette ^f   Mu, Song ^f  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Histone; Pan deacetylase inhibitor; Panobinostat; Phase I; Renal impairment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BJB 432; CALCIUM; CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; MAGNESIUM; METOCLOPRAMIDE; PANOBINOSTAT; POTASSIUM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BJB432; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; NEW DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTERIOSCLEROSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUSE OF DEATH; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELIMINATION HALF-LIFE; END STAGE RENAL DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GEOMETRY; HEMODIALYSIS; HUMAN; ISOTOPE LABELING; KIDNEY CANCER; KIDNEY FUNCTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LUNG EMBOLISM; MAGNESIUM BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT PROLONGATION; RECTUM CANCER; RISK ASSESSMENT; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; SOLID TUMOR; SYSTEMIC THERAPY; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; URINALYSIS; VOLUME OF DISTRIBUTION; BIOTRANSFORMATION; BLOOD; CANCER GRADING; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; HALF LIFE TIME; KIDNEY; KIDNEY FAILURE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT DROPOUTS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DRUG MONITORING; DRUGS, INVESTIGATIONAL; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; KIDNEY; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS; PATIENT DROPOUTS; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84923117253     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2612-8     Document Type: Article

References (20)

1. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241
2. Lane AA, Chabner B.A. (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468
3. Atadja PW (2011) HDAC inhibitors and cancer therapy. Prog Drug Res 67:175-195
4. DeAngelo DJ, Spencer A, Bhalla K.N., Prince HM, Fischer T, Kindler T et al (2013) Phase Ia/II, two-arm, open-label, doseescalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27:1628-1636
5. Ellis L, Pan Y, Smyth G.K., George DJ, McCormack C, Williams-Truax R et al (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510
6. Younes A, Sureda A, Ben-Yehuda D, Zinzani P.L., Ong TC, Prince HM et al (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30:2197-2203
7. San-Miguel J.F., Richardson PG, Gunther A, Sezer O., Siegel D, Blade J et al (2013) Phase ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31:3696-3703
8. Clive S, Woo MM, Nydam T, Kelly L., Squier M, Kagan M. (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70:513-522
9. Wolf JL, Siegel D, Goldschmidt H., Hazell K, Bourquelot PM, Bengoudifa BR et al (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/ refractory multiple myeloma. Leuk Lymphoma 53:1820-1823
10. Fredenhagen A, Kittelmann M, Oberer L., Kuhn A, Kuhnol J, Delemonte T et al (2012) Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589). Drug Metab Dispos 40:1041-1050
11. Slingerland M, Guchelaar HJ, Gelderblom H. (2014) Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25:140-149
12. Anne M, Sammartino D, Barginear M.F., Budman D. (2013) Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther 6:1613-1624
13. Khot A, Dickinson M, Prince H.M. (2013) Panobinostat in lymphoid and myeloid malignancies. Exp Opin Investig Drugs 22:1211-1223
14. Passamonti F, Maffioli M, Caramazza D. (2012) New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol 19:117-123
15. Prince HM, Bishton MJ, Johnstone R.W. (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601-612
16. Slingerland M, Hess D, Clive S., Sharma S, Sandstrom P, Loman N et al (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol 74(5):1089-1098
17. de Estella-Hermoso MA, Imbuluzqueta I, Campanero MA, Gonzalez D, Vilas-Zornoza A, Agirre X et al (2011) Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues. J Chromatogr B Anal Technol Biomed Life Sci 879:3490-3496
18. Bauer S, Hilger RA, Muhlenberg T, Grabellus F., Nagarajah J, Hoiczyk M et al (2014) Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 110:1155-1162
19. Shapiro GI, Frank R, Dandamudi U.B., Hengelage T., Zhao L, Gazi L et al (2012) The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69:555-562
20. Weber HA, Tai F, Paul S., Schindler J, Woo MM, Spence S et al (2009) QT interval measurements in patients with hematologic malignancies and solid tumors treated with oral panobinostat (LBH589). ASH Annu Meet Abstr 114:3781